
PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis
In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of ‘1104 and discuss […]